

# Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study

## Ganz-Exom-Sequenzierung zur Bestimmung von zielgerichteten Therapien für Patientinnen mit metastasiertem Mammakarzinom – eine Machbarkeitsstudie



### Authors

Bernadette Anna Sophia Jaeger<sup>1</sup>, Natalia Krawczyk<sup>1</sup>, Anna Sophia Japp<sup>2</sup>, Ellen Honisch<sup>1</sup>, Karl Köhler<sup>3</sup>, Sibylle Scheuring<sup>3</sup>, Patrick Petzsch<sup>3</sup>, Hans Neubauer<sup>1</sup>, Anne Kathrin Volkmer<sup>1</sup>, Irene Esposito<sup>2</sup>, Eugen Ruckhäberle<sup>1</sup>, Dieter Niederacher<sup>1</sup>, Tanja Fehm<sup>1</sup>

### Affiliations

- 1 Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- 2 Institute of Pathology, University Hospital and Medical Faculty of the Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- 3 Biologisch-Medizinisches Forschungszentrum (BMFZ), Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

### Key words

breast cancer, targeted therapy, whole exome sequencing, decision making platform

### Schlüsselwörter

Mammakarzinom, zielgerichtete Therapie, Ganz-Exom-Sequenzierung, Entscheidungsplattform

received 30.4.2023

accepted after revision 9.8.2023

### Bibliography

Geburtsh Frauenheilk 2023; 83: 1138–1147

DOI 10.1055/a-2150-9440

ISSN 0016-5751

© 2023. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

### Correspondence

Dr. Bernadette Anna Sophia Jaeger  
Department of Obstetrics and Gynecology  
University Hospital and Medical Faculty  
of the Heinrich-Heine University Düsseldorf  
Moorenstr. 5  
40225 Düsseldorf, Germany  
[bernadette.jaeger@med.uni-duesseldorf.de](mailto:bernadette.jaeger@med.uni-duesseldorf.de)

Additional material is available at  
<https://doi.org/10.1055/a-2150-9440>.

### ABSTRACT

#### Introduction

The purpose of this feasibility study was to select targeted therapies according to “ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)”. Data interpretation was further supported by a browser-based Treatment Decision Support platform (MH Guide, Molecular Health, Heidelberg, Germany).

#### Patients

We applied next generation sequencing based whole exome sequencing of tumor tissue and peripheral blood of patients with metastatic breast cancer (n = 44) to detect somatic as well as germline mutations.

#### Results

In 32 metastatic breast cancer patients, data interpretation was feasible. We identified 25 genomic alterations with ESCAT Level of Evidence I or II in 18/32 metastatic breast cancer patients, which were available for evaluation: three copy number gains in *HER2*, two *gBRCA1*, two *gBRCA2*, six *PIK3CA*, one *ESR1*, three *PTEN*, one *AKT1* and two *HER2* mutations. In addition, five samples displayed Microsatellite instability high-H.

## Conclusions

Resulting treatment options were discussed in a tumor board and could be recommended in a small but relevant proportion of patients with metastatic breast cancer (7/18). Thus, this study is a valuable preliminary work for the establishment of a molecular tumor board within the German initiative “Center for Personalized Medicine” which aims to shorten time for analyses and optimize selection of targeted therapies.

## ZUSAMMENFASSUNG

### Einleitung

Ziel dieser Machbarkeitsstudie war es, zielgerichtete Therapien entsprechend der ESCAT-Skala (ESMO Scale for Clinical Actionability of molecular Targets) zu bestimmen. Für die Interpretation der Daten wurde eine browserbasierte Plattform zur Entscheidungsfindung (MH Guide, Molecular Health, Heidelberg, Germany) eingesetzt.

### Patientinnen

Es wurde eine Exomsequenzierung von Tumorgewebe und peripherem Blut von Patientinnen mit metastasiertem Mammakarzinom (n = 44) durchgeführt, um somatische sowie Keimbahnmutationen zu identifizieren.

## Ergebnisse

Bei 32 Patientinnen mit metastasiertem Mammakarzinom konnte eine Dateninterpretation durchgeführt werden. Es wurden 25 genomische Veränderungen (ESCAT-Evidenzstufe I oder II) bei 18/32 Patientinnen mit metastasiertem Mammakarzinom identifiziert und abschließend ausgewertet: darunter fanden sich 3 Fälle mit höheren Vervielfältigungszahlen bei *HER2*, 2 *gBRCA1*-, 2 *gBRCA2*-, 6 *PIK3CA*-, 1 *ESR1*-, 3 *PTEN*-, 1 *AKT1*- und 2 *HER2*-Mutationen. Dazu kamen noch 5 Proben, die hochgradige Mikrosatelliteninstabilität aufwiesen.

## Schlussfolgerung

Die daraus abzuleitenden Behandlungsoptionen wurden in einer Tumorkonferenz diskutiert und dann einer kleinen, aber relevanten Anzahl von Patientinnen mit metastasiertem Mammakarzinom (7/18) empfohlen. Die hier vorgestellte Arbeit stellt eine wertvolle Vorstudie dar, die dazu beitragen kann, molekulare Tumorboards innerhalb des Deutschen Netzwerks für Personalisierte Medizin zu etablieren. Ziel ist, die für Analysen benötigte Zeit zu verkürzen und die Wahl zielgerichteter Therapien zu optimieren.

## Abbreviations

<i>BRCA</i>	BReast CAncer-Gene
CNG	Copy number gain
CNL	Copy number loss
CNV	Copy number variation
DPD	Dihydropyrimidine dehydrogenase
ESCAT	ESMO Scale for Clinical Actionability of molecular Targets
ER	Estrogen receptor
ESMO	European Society for Medical Oncology
GA	Genomic alteration
g	Germline
HER2	Human epidermal growth factor receptor 2
HR	Hormone receptor
LoE	Level of evidence
MBC	Metastatic breast cancer
MSI	Microsatellite instability
PI3K	Phosphoinositide-3-kinase
PARP	Poly-ADP-Ribose-Polymerase
PT	Primary tumor
Rb1	Retinoblastoma 1
TNBC	Triple negative breast cancer
WES	Whole-exome sequencing

## Introduction

Metastatic breast cancer (MBC) is still an incurable disease [1]. Routine therapy options are limited or accompanied by relevant side effects. Therefore, targeted therapy to optimize treatment adherence and outcome has emerged as the preferred approach in past years.

Alongside the decoding of the human genome “precision medicine” moved into the focus and became a reachable goal. The molecular genetic profile of a tumor, a metastatic lesion or even germline status of a patient can give a valuable information in this context [2]. Whole exome sequencing (WES) by identifying genomic alterations (GAs) can give crucial insights into the cellular features which cause and drive cancer development and progression, respectively, and may inform about potential therapeutic targets [3]. GAs detected by next generation sequencing (NGS) include mutations (single nucleotide variants such as missense, nonsense, splice-site mutations) as well as copy number variations (CNV). Identifying cancer-causing and driving genes activated due to somatic CNV partly also led to specific therapeutic approaches [3].

The first targeted therapy for *BReast CAncer*-Gene (*BRCA*)-mutated ovarian cancer was approved in 2014 being the Poly-ADP-Ribose-Polymerase (PARP)-inhibitor olaparib [4]. Meanwhile, further PARP-inhibitors were developed to treat ovarian cancer (niraparib [5] and rucaparib [6]) or approval was gained for *gBRCA*-mutated breast cancer (olaparib and talazoparib) [7, 8], as well as for *BRCA*-mutated metastatic castration-resistant prostate [9] and

pancreatic [10] cancer (olaparib). Therefore, in individual cases targeted therapies approved in other tumor types may also be an option for off-label use. Other GAs provide hints for ineffectiveness or toxicity of certain therapies. There is for example good evidence for mutations in retinoblastoma 1 (Rb1) causing resistance of CDK4/6 inhibitors in MBC patients [11, 12]. Moreover since 2020 it is recommended to test patients for lack of dihydropyrimidine dehydrogenase (DPD) before starting a therapy with fluorouracil or related medicines such as capecitabine [13]. The enzyme DPD is needed to break down fluorouracil, whose enrichment in the blood can lead to severe and life-threatening side effects [13].

However, obtaining information of molecular genetic properties to choose a targeted therapy is still technically challenging and clinical variant interpretation is not trivial. Further the actual challenge of personalized medicine is to combine the clinical information of a specific patient and the molecular properties of his/her tumor with the existing biomedical knowledge to offer a personalized treatment.

To get a comprehensive picture of a patient's GAs we present a feasibility study that explores both the somatic (tumor/metastatic tissues) and germline (white blood cells) mutational status. Therefore, we performed WES of patients with MBC and recommended individualized targeted therapy accordingly.

## Patients, Materials and Methods

### Patients

We identified patients with MBC in our weekly tumor conference. From 2017 to 2020 44 patients with MBC signed written informed consent to participate in our feasibility study "Fighting therapy resistance in patients with solid tumors" (approved by the Ethics Committee of the Medical Faculty of the Heinrich Heine University Düsseldorf; Ref-No: 5673). Inclusion criteria were: metastatic patient with solid tumor; no standard therapy option; Karnowsky-Index >70%; expected life span >6 months. Accordingly, our patient collective was heavily pretreated with several lines of chemo- and/or endocrine therapies.

Hormone receptor (HR) status and Human epidermal growth factor receptor 2 (HER2) amplification was determined according to German clinical routine (immunohistochemistry and/or in situ hybridization analysis). 26/44 (59%) had a HR+ (HER2 non amplified), 7/44 (16%) a HER2 positive (HER2+; HR+ or HR-) and 10/44 (23%) had a triple negative breast cancer (TNBC). They experienced bone and visceral (n=16), visceral only (n=9), cerebral (n=9), bone only (n=1) or other metastatic lesions. Clinical patient data are shown in **Table S1**.

Due to insufficient DNA quality and quantity or failed sequencing procedure only 32 out of the recruited 44 patients were available for WES and data interpretation (**Fig. S1**).

### Blood and tumor tissue

Peripheral blood was obtained by routine vein puncture (two 10 ml EDTA container). Suitable tumor tissue for analyses was identified according to patients' history (preferable most recent metastatic lesion). The tissue was obtained in clinical routine diagnostics. From archived FFPE tissues 5 µm thick sections were pre-

pared and slides were analyzed by experienced pathologists to determine tumor content (at least 20%) by staining with hematoxylin/ eosin and immunohistochemistry. We analyzed tumor tissue from breast, liver, lymph node, brain, skin, lung, or bone.

### DNA extraction and whole-exome sequencing

DNA was purified from FFPE tissue with the GeneRead DNA FFPE Kit (Qiagen, Venlo, the Netherlands). DNA of matched blood and tumor tissue samples were sequenced using the Agilent Sure Select XT V7 or the Illumina IDT Exome Analysis Kit. The libraries were sequenced on a HiSeq 3000 system (Illumina).

### Data Analysis


Anonymized NGS data were transferred via secure VPN channels to a server hosted by Molecular Health GmbH, Heidelberg, Germany. Data were analyzed with the CE-marked in vitro diagnostic software (IVD) MH GUIDE (MH Guide). The MH Guide Variant detection pipeline (MH Guide VDP) uses input sequencing data in (raw) FASTQ format, MH Guide requires for the analysis of paired exomes (WES) of somatic samples a minimum average real coverage of >200 × (the average real coverage is defined as on-target coverage after removal of duplicate read pairs), in which at least 80% of the target region has >100 × average real coverage in the tumor sample. SNVs and Indels that passed the quality filters fulfilled the following quality parameters: PHRED score >28.5, coverage >20 ×, allele frequency >5%, population frequency <1%. The raw sequencing data (reads) are aligned through the MH Guide VDP using standard (GRCh37, HG19) or proprietary population specific human reference genomes (MH PHREGs) based on data from the 1000 genomes project for alignment, using Lofreq (PMID: 23066108) for variant calling for SNVs and atlas and freebayes (<https://arxiv.org/abs/1207.3907>) for Indel calling. The MH Guide VDP provides all detected variants in VCF format for transcript and protein mapping by MH Guide. In paired analyses, all variants detected in the control sample are considered to be germline variants.

For MSI detection MH Guide uses the tool MANTIS (Microsatellite Analysis for Normal-Tumor Instability) to detect MSI biomarkers from FASTQ input [MANTIS tool available at: <https://github.com/OSU-SRLab/MANTIS>] [14]. If the stepwise difference is  $\geq 0.3$ , an MSI-H biomarker is automatically added to the variants list. This threshold of 0.3 is based on validation of 40 TCGA (Cancer Genome Atlas) cases from three cancer entities.

### Data interpretation

MH Guide system screens all GAs identified against the reference information in the proprietary knowledge platform, Dataome. The core of this platform is a manually curated database with evidence-based biomarker information on peer-reviewed published evidence – the so-called clinical variant interpretations (CVIs).

Information captured during the curation process of the CVIs include I) the variant – i.e. the type of genomic aberration (e.g. SNV, Insertion, Deletion etc.); II) the drug or treatment used in the underlying published peer-reviewed evidence (preclinical studies and clinical trials) for which the data source is mainly PubMed; III) the effect of the variant on treatment – i.e. response, resistance or



► **Fig. 1** Twenty-five genomic alterations with potential therapeutical consequences (Level of evidence I-II according to ESMO/ESCAT) detected in 18 metastatic breast cancer patients by next generation sequencing based whole exome sequencing. Five patients had two and one patient three different alterations (CNG = copy number gain, mut = mutation).

safety; IV) the quantity of effect – e.g. strong, medium, weak; V) the observation context (i.e. the disease/disease stage or model system); VI) a link to the underlying evidence and a grading of its reliability. Based on the information provided by the MH Guide platform a GA was classified as “effective” (potential target with therapeutic options), “ineffective” (GA with evidence of less effectiveness or ineffectiveness when certain drugs are applied) and “safety” (GA raising concerns about potential toxicity when administering some medication).

Evidence was further underpinned using the European Society for Medical Oncology (ESMO) classification “ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)” [15]. Clinical decision on therapy options were based on these actual ESCAT evidence tier I and II [16]. In short:

ESCAT evidence tier

- I: “alteration-drug match is associated with improved outcome in clinical trials”
- II: “alteration-drug match is associated with antitumor activity, but magnitude of benefit is unknown”
- III: “alteration-drug match suspected to improve outcome based on clinical trial data in other tumor type(s) or with similar molecular alteration”
- IV: “pre-clinical evidence of actionability”
- X: “lack of evidence for actionability”

## Results

### GAs detected by WES in patients with MBC

Out of the total number of 44 screened MBC patients 32 were available for data evaluation: 21 of these harbored hormone receptor positive (HR+) disease, five presented with HER2+ MBC and six with TNBC. In total we detected 481 GAs in 77 different genes. This comprises 253 mutations, 223 CNVs and five samples showed high microsatellite instability (MSI-H). Most alterations were found in the *XPC* gene (n = 22), followed by the genes *FCGR3A* (n = 19) and *MTHFR* (n = 17) as well as *CYP2 C19* (n = 17), which were exclusively mutations. We detected a minimum of three and a maximum of 32 GAs per patient (median 16.5, mean 15.7).

### ESCAT Level of evidence (LoE) I or II in MBC patients

According to ESMO recommendations 25 GAs from 18 patients belong to ESCAT LoE I or II [16] (see ► **Fig. 1**). Most of the patients (12/18; 67%) had one actionable GA, five had two therapeutic options and one patient had three GAs with two possible therapy recommendations. In ► **Table 1** the detected mutations and the clinical consequences which were taken are listed in detail. The detected alterations of Level IA were: three copy number gains (CNG) in *HER2*, two *gBRCA1*, two *gBRCA2* and six *PIK3CA* mutations. MSI-H as a molecular target of level 1C was identified in five samples. One *ESR1* mutation, three *PTEN* mutations, one *AKT1* mutation and two *HER2* mutations were grouped in Level II A+B.

► **Fig. 1** shows the detected GAs ESCAT LoE I and II according to tumor subtype.

► **Table 1** GAs of our MBC patients with LoE I or II according to ESMO/ESCAT and clinical consequences drawn. Table adapted from [14].

Alterations	LoE	GA in MBC patient	Variant	g/s	VAF	MBC Subtype	Same patient	Targeted Therapy	Consequences
ERBB2 amplification	IA	ERBB2 (CNG)	CN: 4	s	/	HR+	♣	HER2-targeted	3
		ERBB2 (CNG)	CN: 4	s	/	HR+	♥		1 and 5
		ERBB2 (CNG)	CN: 7	s	/	HER2+			1, 2 and 3
Germline BRCA1/2 mutation	IA	BRCA1 p.R1645fs	c.4932_4933dup	g	47.5	HR+	♥	Olaparib	1 and 5
		BRCA1 p.Q1756fs	c.5266dup	g	52.0	HER2+	♦		1
		BRCA2 p.S2835*	c.8504 C>G	g	45.3	HR+	♠		1 and 2
		BRCA2 p.S1271*	c.3812 C>G	g	47.3	HR+			1 and 2
PIK3CA mutation	IA	PIK3CA p.H1047R	c.3140A>G	s	22.1	HR+	\$	Alpelisib	5
		PIK3CA p.H1047R	c.3140A>G	s	57.5	HR+	♣		3
		PIK3CA p.H1047R	c.3140A>G	s	39.8	HR+	°		5
		PIK3CA p.H1047R	c.3140A>G	s	47.1	HR+			#
		PIK3CA p.E545K	c.1633 G>A	s	15.1	HR+	∞		3
		PIK3CA p.E545K	c.1633 G>A	s	20.3	HR+	Ω		3
Microsatellite instability (MSI)	IC	MSI-H	MIS: 0,37	s	/	HR+	◇	Pembrolizumab	#
		MSI-H	MIS: 0,35	s	/	HR+	•		#
		MSI-H	MIS: 0,48	s	/	HR+			4
		MSI-H	MIS: 0,31	s	/	HER2+	♦		#
		MSI-H	MIS: 0,30	s	/	TNBC	&		#
ESR1 mutation	IIA	ESR1 p.Y537C	c.1610A>G	s	25.5	HR+			5
PTEN mutation	IIA	PTEN p.Y225fs	c.673dupT	s	33.8	HR+	~	capiasertib plus fulvestrant	3
		PTEN p.T319fs	c.955dupA	s	43.6	HR+	♠		5
		PTEN p.R130*	c.388 C>G	s	29.5	TNBC	∅		#
AKT1 mutation	IIB	AKT1 p.E17K	c.49 G>A	s	9.0	HR+	•		#
ERBB2 mutation	IIB	ERBB2 p.V777L	c.2329 G>T	s	50.0	HR+	◇	Neratinib	#
		ERBB2 p.V842I	c.2524 G>A	s	52.0	HR+	◇		#

Consequences: 1 = none, known before, 2 = Therapy already taken, 3 = not suitable regarding medical history, 4 = high toxicity expected, 5 = the general health at the time the genetic test result was available did not allow the implementation, # recommended; ♣ ♦ ♥ ♠ • ◇ \$ & ~ Ω ∅ indicating the same patient (see also ► **Table 2**). LoE = Level of evidence, CN = copy number, MIS = microsatellite instability scores above MANTIS cutoff threshold 0.3 [17], g = germline, s = somatic, VAF = variant allele frequency.

Only one out of five patients with HER2+ MBC (HER2 status according to clinical routine assessment) harbored a CNG in *HER2*, based on NGS CNV analysis. Contrarily, CNG in *HER2*, based on NGS CNV analysis, were reported in two of the patients with clinically HR+/HER2- tumor (see ► **Table 1**). Further, in one patient diagnosed with HR+/HER2- tumors we detected two somatic *HER2* mutations (*ERBB2 p.V777L* and *ERBB2 p.V842I*).

In the HR+/HER2- subgroup one patient was carrier of a *gBRCA1* mutation (*BRCA1 p.R1645fs*) and two patients were identified with a *gBRCA2* mutation (*BRCA2 p.S2835\**, *BRCA2 p.S1271\**),

respectively. Interestingly the patient with *gBRCA1* mutation additionally had a somatic *BRCA2* mutation (*BRCA2 p.S3250\**, ESCAT LoE IIIA) and one patient with a *gBRCA2* mutation (*BRCA2 p.S2835\**) also had an *PTEN* mutation (*PTEN p.T319fs*) (please refer to ► **Table 1** and ► **Table 2**). Further, one *gBRCA1* mutation (*BRCA1 p.Q1756fs*) was found in a patient with HER2+ MBC. No *gBRCA* mutations were seen in the subgroup of TNBC patients. All detected *gBRCA* mutations were also confirmed by routine genetic analysis due to young age or family history according the criteria for genetic counselling in Germany [19].

► **Table 2** Genomic alterations of our metastatic breast cancer patients with LoE III and IV according to ESMO/ESCAT. ♥ ∞ \* ◇ & ~ Ω Θ indicating the same patient (see also ► **Table 1**). LoE = level of evidence, g = germline, s = somatic, VAF = variant allele frequency.

Alterations	LoE	GA in MBC patient	Variant	s/g	VAF	Subtyp	Same patient
Somatic BRCA 1/2 mutation	IIIA	BRCA2 p.S3250*	c.9749 C>G	s	30.5	HR+	♥
		BRCA2 p.S368*	c.1103 C>A	s	13.8	HR+	∞
		BRCA2 p.E1879fs	c.5636_5676del	s	14.6	HER2+	*
ARID1A/B	IVA	ARID1A p.Q1330*	c.3988 C>T	s	30.2	TNBC	
ATM mutation	IVA	ATM p.E2837*	c.8509 G>T	s	6.9	HR+	◇
CDH1 mutation	IVA	CDH1 p.Q23*	c.67 C>T	s	28.4	HR+	
		CDH1 p.G877*	c.2629 G>T	s	5.2	HR+	
		CDH1 p.S851*	c.2552 C>A	s	30.1	HR+	∞
		CDH1 p.L466fs	c.1397_1398del	s	22.3	HR+	∞
		CDH1 p.P159fs	c.476del	s	30.7	HR+	\$
MYC	IVA	MYC (CNG)	Copy number 6	s	/	HR+	♣
NF1 mutation	IVA	NF1 p.D1644fs	c.4925_4926ins11	s	19.2	TNBC	&
		NF1 p.S2687fs	c.8059_8060del	s	32.8	HR+	~
TP53 mutation	IVA	TP53 p.R213*	c.637 C>T	s	39.3	HR+	♥
		TP53 p.R248W	c.742 C>T	s	66.2	HR+	
		TP53 p.E294fs	c.881_885del	s	57.5	HR+	°
		TP53 p.E285K	c.853 G>A	s	21.6	HR+	Ω
		TP53 p.E204*	c.610 G>T	s	30.4	HER2+	*
		TP53 p.I232fs	c.694_695ins22	s	16.7	TNBC	&
		TP53 p.Y220C	c.659A>G	s	37.3	TNBC	Θ

All spotted *PIK3CA* mutations (four times *PIK3CA p.H1047R* and twice *PIK3CA p.E545K*) were seen in the subgroup of HR+ patients (29% of HR+ patients) as listed in ► **Table 1**.

MSI-H tumors were detected in all subgroups (three times HR+, once HER2+ and TNBC respectively). The *ESR1 p.Y537C* and the *AKT1 p.E17K* mutation and two of the three *PTEN* mutations (*p.Y225fs* and *p.T319fs*) were found in HR+ MBC patients. One *PTEN* nonsense mutation (*p.R130\**) was detected in a TNBC patient (► **Fig. 1** and ► **Table 1**).

### ESCAT LoE III or IV in MBC

We detected 20 GAs grouped in LoE III or IV according to ESCAT. In Level IIIA we detected two somatic *BRCA2* mutations (*p.S3250\**; *p.S368\**) in the subgroup of HR+/HER2- patients and one somatic *BRCA2* mutation (*p.E1879fs*) in a HER2+ tumor. In LoE IV we found one *ARID1A*, one *ATM*, five *CDH1*, two *NF1* and seven *TP53* mutations, as well as one *MYC* CNG (for detail see ► **Table 2**).


### CNV in known onco-targets

The following known onco-targets [20] with copy number loss were detected in our MBC patients: *RB1* (n = 5), *PTEN* (n = 4), *CDKN2B* (n = 2), *NF1* (n = 5), *SMAD4* (n = 1), *BRCA1* (n = 9), *BRCA2* (n = 4). CNG were identified for *HER2* (n = 3, as already described), *EGFR* (n = 1), *MYC* (n = 1), *PIK3CA* (n = 7), *FGFR1* (n = 5), *FGFR2* (n = 3), *KRAS* (n = 5), *CCND1* (n = 4), *MET* (n = 3), and *CDK6* (n = 4).


### GAs indicating ineffectiveness or safety concerns according to MH Guide

In addition to the actionable targets, we have also identified 92 GAs in 25 different genes that indicate ineffectiveness of a particular drug in patients with MBC (mutations n = 22, MSI-H n = 5, CNV n = 65). From a clinical point of view [11, 21, 22] the most relevant GAs were: *ESR1* (mutation, n = 1; as already described), *RB1* (mutation, n = 2), *CCNE1* (CNG, n = 5), *FGFR1* (CNG, n = 5) and *PIK3CA* (mutation, n = 6; as stated before). In three patients with a *PIK3CA* mutation, we saw evidence of endocrine resistance (whereby various endocrine substances were used in multiple lines of therapy). In the other three cases, endocrine therapy was combined with either a CDK4/6 inhibitor or fulvestrant or HER2-targeted therapy when the subtype changed during the course of the disease, and therefore probably showed a good effect of the respective therapy. Other GAs of clinical interest due to possible ineffectiveness [11, 23, 24, 25, 26] detected in our collective are: *NF1* (CNL, n = 5), *AR* (CNG, n = 4), *CDK6* (CNG, n = 4), *MET* (CNG, n = 3), *HER2* (mutation, n = 2; as specified above), *LRP1B* (CNL, n = 2) and *FGFR2* (CNG, n = 1) (see ► **Fig. 2**).

The *RB1* mutations (*RB1 p.L199fs* and *RB1 p.E184*) and three of the *CCNE1* CNG were seen in the HR+/HER2- subgroup which may cause failure of CDK4/6 treatment. Further *ESR1* mutation and *FGFR1* CNG can be associated with endocrine resistance and was also altered exclusively in this subgroup. However, *PIK3CA* muta-



► **Fig. 2** Genomic alterations with potential ineffectiveness concerning certain therapies according to MH Guide detected by next generation sequencing based whole exome sequencing in our metastatic breast cancer patients (multiple genomic alterations per patient possible; CNG = copy number gain, CNL = copy number loss, mut = mutation).



► **Fig. 3** Genomic alterations with potential toxicity concerning certain therapies according to MH Guide detected by next generation sequencing based whole exome sequencing in our metastatic breast cancer patients (multiple genomic alterations per patient possible).

tions (as mentioned above), which may indicate trastuzumab resistance, were also detected exclusively in the HR+/HER2- subgroup, therefore without clinical consequences in our patient collective (► **Fig. 2** shows the GAs with potential ineffectiveness according to MBC subtype).

Toxicity concerns were raised for 214 GAs in 22 different genes, with mutations in *XPC* (n = 22), *FCGR3A* (n = 19), *MTHFR* (n = 17), *CYP2 C19* (n = 17) and *CYP2 D6* (n = 16) being the most altered

ones (see ► **Fig. 3**). A *DPD* mutation was identified in four patients (two HR+ and two TNBC), which is highly important from a clinical perspective as it increases the likelihood of relevant adverse events during therapy with fluorouracil. Further we detected three *EGFR* mutations, which may be a driver of tumorigenesis in breast cancer and/or may indicate therapy resistance since these GAs have been found to develop under drug pressure [27] (► **Fig. 3** shows the GAs with potential toxicity according to MBC subtype).

## Discussion

Here we present a feasibility study performing NGS-based WES in patients with MBC. We have established a working procedure for patient recruitment, sample collection, collaboration between different institutions and discussion of the results in a tumor board. Due to the availability of new targeted therapies whose indications are based on GAs, there is an increasing need for genetic analyses at an early timepoint of metastatic/advanced breast cancer. Because of tumor heterogeneity and changes during carcinogenesis or the metastatic process, several analyses during the course of disease may even be useful and necessary (e.g. regarding a somatic *PIK3CA* mutation) [28, 29]. In 2017 the FDA approved two comprehensive mid-size panels for genetic testing in cancer (Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) and FoundationOne CDx) which addressed the unmet need for precision oncology [30]. Nevertheless, it is a question of time, costs, and technical equipment to be able to perform genetic tests and, above all, to make them available for clinical use. For instance the relatively high dropout rate (25%) of our patient population due to sample errors (too little tumor tissue or insufficient DNA quality) is in line with data published by another research group [31]. For clinical decision-making it is further necessary to know the patient's medical history in detail, which is essential and must be included in the discussion of treatment decisions in a molecular tumor board.

We identified 481 GAs in patients with MBC. These include CNV, mutations and MSI-H. According to the 2019 ESMO criteria for MBC, 25 GAs were classified as ESCAT LoE I–II. In 7/18 patients with MBC (39%), we were able to recommend targeted therapy accordingly [32] with one patient having two options and one patient having two GAs leading to the same therapy recommendation (see ► **Table 1**). Precisely we suggested four times pembrolizumab if MSI-H was detected, once alpelisib for a *PIK3CA* mutation, once capivasertib plus fulvestrant if there was a *PTEN* loss-of-function mutation, once capivasertib plus fulvestrant for an *AKT* mutation and after reevaluation of the “likely pathogenic” *HER2* mutations we could recommend neratinib in one patient diagnosed as *HER2*- MBC. In six patients, the possible targeted therapy was not suitable due to the individual medical history. This means that concomitant diseases did not allow the administration of the matching drug, or the concomitant medication did not fulfil the approval. Once, the high probability of side effects and the patient's advanced age spoke against the optional targeted therapy. Unfortunately, the general health of six patients at the time the genetic test result was available did not allow the implementation of potential targeted therapy. In three patients no additional therapeutic recommendations were made after WES, mainly because appropriate targeted therapies were already in use based on findings of routine diagnostic (*HER2*-targeted therapies or the PARP-inhibitor olaparib). However, this also means that we recognize these findings in clinical routine and do not miss these GAs (please refer to ► **Table 1** for details).

The differences in *HER2* status detected by NGS (*HER2* CNG) compared to immunohistochemistry or FISH could be explained by tumor heterogeneity [33, 34] or by changes in *HER2* status during the course of the disease [35], which are common phenomena

in MBC. In addition, intermetastatic heterogeneity is a described phenomenon that arises under therapy pressure, as different cell clones may respond differently or escape certain therapies. Personalized therapy aims to treat a tumor according to its genetic characteristics, which are homogeneous in the vast majority of cancer cases at diagnosis, rather than applying a standard therapy to all patients with a specific cancer type. [36]. *HER2* mutations occur in approximately 2% of patients with breast cancer and could expand treatment options to targeted *HER2* therapy in patients with *HER2*- PT. In our collective, we detected two likely pathogenic *HER2* mutations (6%), which is significantly more compared to the current literature [37]. This may be explained mainly due to our small number of patients. Hempel et al. detected an *HER2* amplification by NGS in nine out of 41 patients with advanced breast cancer (out of which seven had a *HER2*+ tumor by immunohistochemistry and/or in situ hybridization) and *HER2* mutation in two patients. They conclude that a threshold must be defined on basis of CNV to allow a better interpretation of NGS based amplification analysis. Further, performing NGS analyses they could recommend promising treatment options according ESCAT Level I in 58.5% of their patients (*HER2* mutation n = 9, *PIK3CA* mutation n = 14, MSI n = 1) [38].

Consequently, according to our results and those of others, targeted therapy based on molecular findings is appropriate for a significant proportion of patients [39]. In this context, the selection of suitable patients and definition of targets are crucial [31, 38, 40, 41].

Due to the late stage of disease or irrelevance for the current treatment option none of the inefficacy or safety concerns based on GAs changed our clinical therapy decision. However, in earlier stage of disease the detected GAs may give valuable hints concerning possible ineffectiveness or relevant toxicity of certain therapies. In this context, Reinhardt et al. screened 1270 patients with early breast cancer for the presence of *PIK3CA* mutations and found a significant influence on the effect of adjuvant aromatase inhibitors but no influence on the efficacy of adjuvant tamoxifen [18]. Similar to ESCAT a validated classification of these GAs is highly needed for clinical routine. According to the experts, due to its high clinical relevance, the *ESR1* mutation, for example, although indicating endocrine resistance, was included in ESCAT.

Focus of our feasibility study was to identify possibly druggable molecular targets. Besides, using WES we further detected several CNV which until now have no suitable therapeutic agent or at least there is no sufficient clinical data. Their relevance stems from the fact that the expression level of a gene strongly correlates with its copy number [17, 20]. Somatic CNV typically arise during carcinogenesis and, if resulting in the deletion of tumor suppressor genes or the amplification of oncogenes, they are usually pathogenic [20].

Although we were able to implement the NGS based diagnostic workflow for patients with MBC in our center, several limitations must be considered. Different tumor cell clones harboring different somatic mutations can divide a cancer into several subgroups (heterogeneity). In this context, the prognosis and response to treatment can be very unique for each clone [20]. In addition, the genomic profile of biopsy tissues provides a picture that is limited to only a single point in space and time. This may lead to an

under-representation of intratumor heterogeneity [42], limiting the predictive value of a single tissue biopsy as in our study. Other limitations of our work are, first, the heterogeneous patient population recruited in routine clinical practice without randomization, follow-up, or survival data. Secondly, missing or very late tissue samples of varying quality and highly variable time points in the disease course and thirdly, the long processing time as well as the software for data evaluation, which could overlook GAs.

In line with ESMO recommendations, our data show that large gene panels and routine use of NGS result in few clinically significant responders. Nevertheless, the patient and physician may decide together to perform a large gene panel if the patient is informed that the likelihood of benefit is rather low. According to ESMO, the use of off-label drugs matched to GAs is only recommended when an access program and decision-making process are available [39].

Consequently, the German initiative “Center for Personalized Medicine” established structured access to a molecular tumor board and interdisciplinary case discussion.

## Conclusion

In this feasibility study we demonstrate that WES using NGS for patients with MBC is technically possible and feasible. However, in oncology practice there are no recommendations from scientific societies about its use in daily routine [39]. Due to the low detection rate of truly actionable GAs leading to therapeutic consequences genetic testing is recommended only for a selected patient collective. In this context the molecular tumor board is an essential instrument to choose appropriate patients and discuss the results in an interdisciplinary setting. The identification of drugable molecular alterations among many possible targets and especially among the various alterations of the same target, is crucial. ESCAT provides a useful continuously updated tool for classifying GAs according to their clinical relevance which assists clinicians in delivering accurate and individualized indications for the patients [32]. The browser-based Treatment Decision Support platform MH Guide can further help interpret the abundance of genetic data.

## Supplement

- **Fig. S1:** Study cohort and flowchart (MBC = metastatic breast cancer, WES = whole exome sequencing).
- **Table S1:** Patient collective.

## Fundings

| Förderung Krebsforschung Nordrhein-Westfalen e.V. |

## Acknowledgement

We thank our technicians and the study office for their continuous assistance and dedicated work. Computational support of the “Zentrum für Informations- und Medientechnologie”, especially the HPC team (High Performance Computing) at the Heinrich-Heine University is acknowledged. As this work was funded by the “Förderung Krebsforschung Nordrhein-Westfalen e. V.” ([www.krebsforschung-nrw.de](http://www.krebsforschung-nrw.de)), we thank them for their financial support. Finally, we would like to express our sincere gratitude to the patients who participated in the study.

## Conflict of Interest

The authors declare that they have no conflict of interest.

## References

- [1] Cardoso F, Senkus E, Costa A et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). *Ann Oncol* 2018; 29: 1634–1657. doi:10.1016/j.annonc.2020.09.010
- [2] Priestley P, Baber J, Lolkema MP et al. Pan-cancer whole-genome analyses of metastatic solid tumours. *Nature* 2019; 575: 210–216. doi:10.1038/s41586-019-1689-y
- [3] Beroukhi R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010; 463: 899–905. doi:10.1038/nature08822
- [4] Ledermann J, Harter P, Gourley C et al. Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. *Obstet Gynecol Surv* 2014; 69: 594–596
- [5] González-Martín A, Pothuri B, Vergote I et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019; 381: 2391–2402. doi:10.1056/NEJMoa1910962
- [6] Holloway RW, Gancedo MA, Fong PC et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2018; 390: 1949–1961. doi:10.1016/S0140-6736(17)32440-6
- [7] Robson M, Im SA, Senkus E et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med* 2017; 377: 523–533. doi:10.1056/NEJMoa1706450
- [8] Litton JK, Rugo HS, Ettl J et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* 2018; 379: 753–763. doi:10.1056/NEJMoa1802905
- [9] de Bono J, Mateo J, Fizazi K et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2020; 382: 2091–2102. doi:10.1056/NEJMoa1911440
- [10] Golan T, Hammel P, Reni M et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* 2019; 381: 317–327. doi:10.1056/NEJMoa1903387
- [11] Scheidemann ER, Shajahan-Haq AN. Resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. *Int J Mol Sci* 2021; 22: 12292. doi:10.3390/ijms222212292
- [12] Ono M, Oba T, Shibata T et al. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. *J Cancer Res Clin Oncol* 2021; 147: 3211–3224. doi:10.1007/s00432-021-03722-3
- [13] European Medicines Agency. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. *Eur Med Agency* 2020; 31: 3

- [14] Kautto EA, Bonneville R, Miya J et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. *Oncotarget* 2017; 8: 7452–7463. doi:10.18632/oncotarget.13918
- [15] Mateo J, Chakravarty D, Dienstmann R et al. A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol* 2018; 29: 1895–1902. doi:10.1093/annonc/mdy263
- [16] Condorelli R, Mosele F, Verret B et al. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol* 2019; 30: 365–373. doi:10.1093/annonc/mdz036
- [17] Chang Z, Liu X, Zhao W et al. Identification and Characterization of the Copy Number Dosage-Sensitive Genes in Colorectal Cancer. *Mol Ther Methods Clin Dev* 2020; 18: 501–510. doi:10.1016/j.omtm.2020.06.020
- [18] Reinhardt K, Stückerath K, Hartung C et al. PIK3CA-mutations in breast cancer. *Breast Cancer Res Treat* 2022; 196: 483–493. doi:10.1007/s10549-022-06637-w
- [19] Kast K, Rhiem K, Wappenschmidt B et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. *J Med Genet* 2016; 53: 465–471. doi:10.1136/jmedgenet-2015-103672
- [20] Liu B, Morrison CD, Johnson CS et al. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: Principles and challenges. *Oncotarget* 2013; 4: 1868–1881. doi:10.18632/oncotarget.1537
- [21] Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer Res* 2010; 70: 2085–2094. doi:10.1158/0008-5472.CAN-09-3746
- [22] Majewski IJ, Nuciforo P, Mittempergher L et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. *J Clin Oncol* 2015; 33: 1334–1339. doi:10.1200/JCO.2014.55.2158
- [23] Minuti G, Cappuzzo F, Duchnowska R et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. *Br J Cancer* 2012; 107: 793–799. doi:10.1038/bjc.2012.335
- [24] Chandarlapaty S, Sakr RA, Giri D et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. *Clin Cancer Res* 2012; 18: 6784–6791. doi:10.1158/1078-0432.CCR-12-1785
- [25] Giovannelli P, Di Donato M, Galasso G et al. The androgen receptor in breast cancer. *Front Endocrinol (Lausanne)* 2018; 9: 492. doi:10.3389/fendo.2018.00492
- [26] Serio PAMP, de Lima Pereira GF, Katayama MLH et al. Somatic mutational profile of high-grade serous ovarian carcinoma and triple-negative breast carcinoma in young and elderly patients: Similarities and divergences. *Cells* 2021; 10: 3586. doi:10.3390/cells10123586
- [27] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. *Mol Oncol* 2018; 12: 3–20. doi:10.1002/1878-0261.12155
- [28] Jensen JD, Laenkholm A, Knoop A. PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer. *Clin Cancer Res* 2011; 17: 667–677. doi:10.1158/1078-0432.CCR-10-1133
- [29] Fusco N, Malapelle U, Fassin M et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Front Oncol* 2021; 11: 644737. doi:10.3389/fonc.2021.644737
- [30] Allegretti M, Fabi A, Buglioni S et al. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. *J Exp Clin Cancer Res* 2018; 37: 47. doi:10.1186/s13046-018-0702-x
- [31] Van Geelen CT, Savas P, Teo ZL et al. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. *Breast Cancer Res* 2020; 22: 91. doi:10.1186/s13058-020-01328-0
- [32] Crimini E, Repetto M, Aftimos P et al. Precision medicine in breast cancer: From clinical trials to clinical practice. *Cancer Treat Rev* 2021; 98: 102223. doi:10.1016/j.ctrv.2021.102223
- [33] Ohlschlegel C, Zahel K, Kradolfer D et al. HER2 genetic heterogeneity in breast carcinoma. *J Clin Pathol* 2011; 64: 1112–1116. doi:10.1136/jclinpath-2011-200265
- [34] Van Bockstal MR, Agahozo MC, van Marion R et al. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification. *Mol Oncol* 2020; 14: 671–685. doi:10.1002/1878-0261.12650
- [35] Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. *J Clin Oncol* 2012; 30: 593–599. doi:10.1200/JCO.2010.33.8889
- [36] Reiter JG, Baretta M, Gerold JM et al. An analysis of genetic heterogeneity in untreated cancers. *Nat Rev Cancer* 2019; 19: 639–650. doi:10.1038/s41568-019-0185-x
- [37] Ross JS, Gay LM, Wang K et al. Non-Amplification ERBB2 Genomic Alterations in 5,605 Cases of Relapsed and Metastatic Breast Cancer: an Emerging Opportunity for anti-HER2 Targeted Therapies. *Cancer* 2016; 122: 2654–2662. doi:10.1002/cncr.30102
- [38] Hempel D, Ebner F, Garg A et al. Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. *Sci Rep* 2020; 10: 10459. doi:10.1038/s41598-020-67393-9
- [39] Mosele F, Remon J, Mateo J et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol* 2020; 31: 1491–1505. doi:10.1016/j.annonc.2020.07.014
- [40] Sultova E, Westphalen CB, Jung A et al. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU. *Arch Gynecol Obstet* 2021; 303: 1331–1345. doi:10.1007/s00404-020-05881-z
- [41] Sivapiragasam A, Ashok Kumar P, Sokol ES et al. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. *Cancer Med* 2021; 10: 53–61. doi:10.1002/cam4.3550
- [42] Reinhardt F, Franken A, Fehm T et al. Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies? *Tumor Biol* 2017; 39: 1010428317731511. doi:10.1177/1010428317731511